Skip to content
Alivexis, Inc.
Unveiling the Future of Medicine
Menu
Home
Science
Pipeline
About Us
News
Public Notice
Contact Us
日本語
News
News
Melodia Therapeutics and Alivexis Sign Exclusive License Agreement for Cathepsin C Inhibitor Program MOD-A
- 21 June, 2024
Alivexis with Astellas Pharma Inc. to Collaborate on Novel Drug Target
- 17 June, 2024
Joint Research on Novel Anti-Allergic Disease Drug Candidate Published by Alivexis, Inc. and University of Yamanashi
- 11 April, 2024
Modulus Discovery, Inc. to Change Its Name to Alivexis, Inc. on March 11, 2024
- 11 March, 2024
Modulus Discovery, Inc. to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- 09 January, 2024
PeptiDream and Modulus Announce Nomination of First Clinical Development Candidate from Strategic Partnership
- 03 August, 2023
Modulus Discovery has been selected as a “J-Startup” company by the Ministry of Economy, Trade and Industry of Japan
- 06 April, 2023
Modulus Discovery, Inc. to Present at the 41st Annual J.P. Morgan Healthcare Conference
- 13 December, 2022
Modulus Discovery Announces Research Collaboration with Fujitsu on the Implementation and Optimization of ModBind™, A Novel Computational Technology for Drug Discovery
- 08 August, 2022
Modulus Discovery Closes $20.4M USD Series C
- 01 March, 2022
Previous
Next
Press & Media Contact
Email address protected by JavaScript.
Please enable JavaScript to contact me.
Latest Release
Alivexis Announces Receipt of Intention to Exercise Option Right from Astellas Pharma Inc. for Collaboration on Novel Drug Target
Notice of Selection for the Ministry of Economy, Trade and Industry’s Domestic Generative AI Development Strengthening Project “GENIAC”
Alivexis to Present at the 2025 BIO International Convention
Alivexis To Present at GTC 2025 Japan AI Day
Alivexis Raises $0.7M USD Series D in Second Close
